SCHEMBL5342883

SCHEMBL5342883

O=C(NCCc1c[nH]c2ccc(O)cc12)c1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.75
TRPV1 Q8NER1 5/20 0.74
PTGS1 P23219 4/20 0.74
PTGS2 P35354 2/20 0.74
MEN1 O00255 1/20 0.74
NPC1 O15118 1/20 0.74
RAB9A P51151 1/20 0.74
KMT2A Q03164 1/20 0.74
SPR P35270 2/20 0.69
KDM4E B2RXH2 1/20 0.69
ALDH1A1 P00352 1/20 0.69
CYP1A2 P05177 1/20 0.69
CYP3A4 P08684 1/20 0.69
CYP2D6 P10635 1/20 0.69
MAPT P10636 1/20 0.69
IDO1 P14902 1/20 0.69
HPGD P15428 1/20 0.69
BLM P54132 1/20 0.69
NOTUM Q6P988 1/20 0.69
NPSR1 Q6W5P4 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31277254 1.00 ACHE (0.75) ACHETRPV1PTGS1PTGS2MEN1
SCHEMBL7019674 0.93 ACHE (0.66) ACHETRPV1PTGS1PTGS2MEN1
SCHEMBL28412156 0.90 PTGS1 (0.77) ACHETRPV1PTGS1PTGS2MEN1
SCHEMBL10071693 0.89 TYR (0.81) ACHETRPV1PTGS1PTGS2MEN1
SCHEMBL25217961 0.88 TRPV1 (0.67) ACHETRPV1PTGS1PTGS2MEN1
SCHEMBL20182262 0.88 TRPV1 (0.73) ACHETRPV1PTGS1PTGS2KMT2A
SCHEMBL15145405 0.87 PTGS1 (0.81) ACHETRPV1PTGS1PTGS2MEN1
SCHEMBL5341652 0.86 MEN1 (0.73) TRPV1MEN1NPC1RAB9AKMT2A
SCHEMBL5343192 0.86 KMT2A (0.73) ACHETRPV1MEN1NPC1RAB9A
SCHEMBL794173 0.86 TYR (0.70) ACHETRPV1PTGS1PTGS2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174510-A1 N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof EMORY UNIVERSITY 2023-06-08 US disclosed
US-20230174510-A1 N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof EMORY UNIVERSITY 2023-06-08 US disclosed
EP-4142714-A1 N-ACETYLSEROTONIN DERIVATIVES AS TRKB ACTIVATORS AND USES THEREOF Emory University (US) 2023-03-08 EP disclosed
US-20130196050-A1 SALTY TASTE ENHANCER AJINOMOTO CO., INC. (JP) 2013-08-01 US disclosed
US-7183318-B2 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2007-02-27 US disclosed
US-7126012-B2 Substituted cyclic compounds LES LABORATOIRES SERVIER (FR) 2006-10-24 US disclosed
US-7115752-B2 Substituted cyclic compounds LES LABORATOIRES SERVIER (FR) 2006-10-03 US disclosed
US-20050124682-A1 Substituted cyclic compounds LESIEUR DANIEL (FR) 2005-06-09 US disclosed
US-6872851-B1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them LES LABORATORIES SERVIER (FR) 2005-03-29 US disclosed
US-20050059729-A1 Substituted cyclic compounds LESIEUR DANIEL (FR) 2005-03-17 US disclosed
US-20040002490-A1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them LESIEUR DANIEL (FR) 2004-01-01 US disclosed
US-20040002491-A1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them LESIEUR DANIEL (FR) 2004-01-01 US disclosed
US-6605632-B1 Affinity for melatonin receptors LES LABORATOIRES SERVIER (FR) 2003-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196050-A1 SALTY TASTE ENHANCER TAS2R10, TAS2R5, TAS1R1 ACHE 1300/4885TRPV1 458/4885PTGS1 1229/4885
US-20230174510-A1 N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof BDNF, NTRK2, NGF ACHE 545/4885TRPV1 190/4885PTGS1 2650/4885
US-20050059729-A1 Substituted cyclic compounds CCNY, CCNT2, TECR ACHE 1165/4885TRPV1 2763/4885PTGS1 1712/4885
US-20040002491-A1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them CYP4B1, CYP3A5, MC2R ACHE 1880/4885TRPV1 2408/4885PTGS1 616/4885
US-20050124682-A1 Substituted cyclic compounds CCNY, CCNT2, TECR ACHE 1165/4885TRPV1 2763/4885PTGS1 1712/4885
US-20040002490-A1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them CYP3A5, CYP4B1, MC2R ACHE 1899/4885TRPV1 2372/4885PTGS1 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.